Near infra-red light treatment of Alzheimer’s disease

Han, Mengmeng; Wang, Qiyan; Xue, Wei; Zeng, Yuhui; Huang, Yong; Meng, Qingqiang; Zhang, Jun; Wei, Xunbin

doi:10.1142/s1793545817500122

Cited by 11 publications

(16 citation statements)

References 29 publications

(35 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We also tested the 1070-nm light pulsed at 40 Hz, with the same average power density and total fluence applied to compare the differences of therapeutic effects influenced only by the pulse frequency of light. Based on previous results 25 , the wavelength of the LED array was chosen as 1070 ± 50 nm, and the average power density was 25 mW/cm 2 . The transmittances of incident 1070-nm light were summarized in Fig.…”

Section: Resultsmentioning

confidence: 99%

“…There is compelling evidence suggested that PBM is capable of decreasing Aβ burden in the plasma 17 , cerebrospinal fluid 17 , and brain 19 in AD models. A previous study from our group demonstrated the therapeutic effects of continuous-wave light with a wavelength of 1070 nm on memory abilities and Aβ burden in an AD mouse model 25 . Similarly, Grillo et al demonstrated the beneficial effects of 1070-nm light on Aβ and phosphorylated tau protein levels in the brains of AD mice 15 .…”

Section: Introductionmentioning

confidence: 91%

See 1 more Smart Citation

Microglia modulation with 1070-nm light attenuates Aβ burden and cognitive impairment in Alzheimer’s disease mouse model

et al. 2021

Self Cite

View full text Add to dashboard Cite

Photobiomodulation, by utilizing low-power light in the visible and near-infrared spectra to trigger biological responses in cells and tissues, has been considered as a possible therapeutic strategy for Alzheimer’s disease (AD), while its specific mechanisms have remained elusive. Here, we demonstrate that cognitive and memory impairment in an AD mouse model can be ameliorated by 1070-nm light via reducing cerebral β-amyloid (Aβ) burden, the hallmark of AD. The glial cells, including microglia and astrocytes, play important roles in Aβ clearance. Our results show that 1070-nm light pulsed at 10 Hz triggers microglia rather than astrocyte responses in AD mice. The 1070-nm light-induced microglia responses with alteration in morphology and increased colocalization with Aβ are sufficient to reduce Aβ load in AD mice. Moreover, 1070-nm light pulsed at 10 Hz can reduce perivascular microglia and promote angiogenesis to further enhance Aβ clearance. Our study confirms the important roles of microglia and cerebral vessels in the use of 1070-nm light for the treatment of AD mice and provides a framework for developing a novel therapeutic approach for AD.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 91%

Microglia modulation with 1070-nm light attenuates Aβ burden and cognitive impairment in Alzheimer’s disease mouse model

et al. 2021

Self Cite

View full text Add to dashboard Cite

show abstract

“…As for the studies described in the results and referring to those that used animal models, the photobiomodulation, with the different protocols tested, brought together some results. Results described in in vivo studies using animal models showed reduction of hyper phosphorylation of the tau protein, attenuation of neurofibrillary tangles, decreased oxidative stress markers, reduced deposition, number, and size of β-amyloid plaques, reduced neuronal loss, formaldehyde dehydrogenase activation, positive influence on the flow of interstitial fluids, and capacity to recover and improve cognitive functions, such as learning and spatial memory capacity [30][31][32][33][34].…”

Section: Transcranial Photobiomodulationmentioning

confidence: 94%

“…Han et al [31] used animal model C57BL/6 J, being females divided into 3 groups: rats without irradiation (n = 10), rats with irradiation (n = 10), and normal rats without irradiation (n = 12). The therapeutic adopted was LED with wavelengths between 1040 nm and 1090 nm, power of 15 mW/cm2; 6 minutes a day, for 40 days, suspended for 28 days, and then starting the treatment again for another 15 days.…”

Section: Transcranial Photobiomodulation (Using Led)mentioning

confidence: 99%

Therapeutic Approaches for Alzheimer’s Disease: New Perspectives

Kerppers¹,

Hosni²,

Miri³

et al. 2022

Amyloidosis - History and Perspectives

View full text Add to dashboard Cite

Alzheimer’s disease (AD) was defined as a neurodegenerative disorder, being more affected in the elderly. It is estimated that every 3.2 seconds a person in the world is affected by the high disease that rate in 2050 to 1 second. Therefore, research has been carried out on new therapeutic approaches, such as Transcranial Photobiomodulation and treatment based on antioxidants, such as Resveratrol. Therefore, the objective is to conduct a literature review on these two approaches and their effects on the treatment of AD. It was carried out according to the PRISMA recommendation and the articles were selected according to the years of publication (between 2015 and 2020) and extracted from the following databases: Science Direct, PubMed PMC, Scopus, PubMed NCBI, SciELO, LILACS, MEDLINE and PEDro. In several studies it has been reported that both therapies provide improvements at the molecular and behavioral level, recovering brain functions, acting in a neuroprotective way, improving quality of life, with few adverse effects and in a less invasive way. Thus, both treatments have numerous benefits that can be useful in the treatment of AD. However, there is a need for further research that includes interventions with greater specificity and control, so that they are defined as ideal doses and treatment protocols.

show abstract

“…The studies on using visible and near infrared light have suggested that these non-pharmacological and noninvasive treatments have the potential to improve AD due to their ability to alleviate pathology and cognitive dysfunction in AD mice [ 23 – 26 ]. As we know, sunlight has three major components: ultraviolet light, visible light and infrared radiation [ 27 ], and these lights also have multiple sub-divisions, such as near infrared light, middle infrared light and far infrared light.…”

Section: Introductionmentioning

confidence: 99%

Far infrared light irradiation enhances Aβ clearance via increased exocytotic microglial ATP and ameliorates cognitive deficit in Alzheimer’s disease-like mice

Peng

Luo

et al. 2022

J Neuroinflammation

View full text Add to dashboard Cite

Background Exposure to sunlight may decrease the risk of developing Alzheimer’s disease (AD), and visible and near infrared light have been proposed as a possible therapeutic strategy for AD. Here, we investigated the effects of the visible, near infrared and far infrared (FIR) light on the cognitive ability of AD mice, and found that FIR light also showed potential in the improvement of cognitive dysfunction in AD. However, the related mechanism remains to be elucidated. Methods Morris water maze was used to evaluate the cognitive ability of APPswe/PSEN1dE9 double-transgenic AD mice after light treatment. Western blot was carried out to detect the expression of protein involved in synaptic function and amyloid-β (Aβ) production. The protein amount of interleukin (IL)-1β, IL-6, Aβ1-40 and Aβ1-42 were determined using enzyme-linked immunosorbent assay. The mRNA level of receptors was performed using real-time quantitative polymerase chain reaction. Immunostaining was performed to characterize the Aβ burden and microglial Aβ phagocytosis in the brain of AD mice. The Aβ phagocytosis of primary cultured microglia and BV2 were assessed by flow cytometry. The energy metabolism changes were evaluated using related assay kits, including adenosine triphosphate (ATP), lactate content, mitochondrial respiratory chain complex enzymatic activity and oxidized/reduced nicotinamide adenine dinucleotide assay kits. Results Our results showed that FIR light reduced Aβ burden, a hallmark of AD neuropathology, alleviated neuroinflammation, restored the expression of the presynaptic protein synaptophysin, and ameliorated learning and memory impairment in the AD mice. FIR light enhanced mitochondrial oxidative phosphorylation pathway to increase ATP production. This increased intracellular ATP promoted the extracellular ATP release from microglia stimulated by Aβ, leading to the enhanced Aβ phagocytosis through phosphoinositide 3-kinase/mammalian target of rapamycin pathways for Aβ clearance. Conclusions Our findings have uncovered a previously unappreciated function of FIR light in inducing microglial phagocytosis to clean Aβ, which may be the mechanisms for FIR light to improve cognitive dysfunction in AD mice. These results suggest that FIR light treatment is a potential therapeutic strategy for AD.

show abstract

Near infra-red light treatment of Alzheimer’s disease

Cited by 11 publications

References 29 publications

Microglia modulation with 1070-nm light attenuates Aβ burden and cognitive impairment in Alzheimer’s disease mouse model

Microglia modulation with 1070-nm light attenuates Aβ burden and cognitive impairment in Alzheimer’s disease mouse model

Therapeutic Approaches for Alzheimer’s Disease: New Perspectives

Far infrared light irradiation enhances Aβ clearance via increased exocytotic microglial ATP and ameliorates cognitive deficit in Alzheimer’s disease-like mice

Contact Info

Product

Resources

About